GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP grew its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 15.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,472 shares of the company's stock after buying an additional 7,937 shares during the period. Artemis Investment Management LLP's holdings in GE HealthCare Technologies were worth $4,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Quent Capital LLC lifted its position in GE HealthCare Technologies by 18.4% in the third quarter. Quent Capital LLC now owns 766 shares of the company's stock valued at $72,000 after acquiring an additional 119 shares during the last quarter. Greenleaf Trust grew its stake in GE HealthCare Technologies by 1.7% during the 3rd quarter. Greenleaf Trust now owns 7,619 shares of the company's stock worth $715,000 after buying an additional 124 shares during the last quarter. Westside Investment Management Inc. grew its stake in GE HealthCare Technologies by 32.0% during the 3rd quarter. Westside Investment Management Inc. now owns 516 shares of the company's stock worth $48,000 after buying an additional 125 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in GE HealthCare Technologies by 8.7% in the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company's stock valued at $135,000 after buying an additional 127 shares during the last quarter. Finally, Quarry LP boosted its holdings in shares of GE HealthCare Technologies by 28.3% in the second quarter. Quarry LP now owns 594 shares of the company's stock valued at $46,000 after acquiring an additional 131 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GEHC. Wells Fargo & Company lifted their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and increased their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Stifel Nicolaus boosted their price target on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Evercore ISI increased their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, UBS Group lowered GE HealthCare Technologies from a "neutral" rating to a "sell" rating and dropped their target price for the company from $84.00 to $74.00 in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.00.

Insider Buying and Selling

In related news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company's stock.

GE HealthCare Technologies Price Performance

Shares of GEHC traded down $0.26 during trading hours on Monday, reaching $84.74. The company had a trading volume of 2,855,039 shares, compared to its average volume of 2,724,028. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a 12-month low of $71.31 and a 12-month high of $94.55. The firm has a 50 day simple moving average of $81.98 and a 200-day simple moving average of $84.43. The company has a market capitalization of $38.72 billion, a price-to-earnings ratio of 23.28, a PEG ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company's revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the firm earned $0.99 EPS. Research analysts expect that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. The ex-dividend date is Tuesday, January 14th. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. GE HealthCare Technologies's payout ratio is 3.30%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.